These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 19948450

  • 1. [First line chemotherapy of advanced epithelial ovarian cancer].
    Lhommé C, Even C, Morice P, Balleyguier C, Petrella M, Gouy S, Uzan C, Duvillard P, Pautier P.
    Bull Cancer; 2009 Dec; 96(12):1207-13. PubMed ID: 19948450
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
    Mayerhofer K, Bodner-Adler B, Bodner K, Leodolter S, Kainz C.
    Anticancer Res; 2000 Dec; 20(5C):4047-50. PubMed ID: 11268499
    [Abstract] [Full Text] [Related]

  • 3. [Combined chemotherapy with weekly paclitaxel and carboplatin for recurrent and refractory epithelial ovarian cancer--phase I study].
    Misawa A, Yasuda M.
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1445-52. PubMed ID: 17033235
    [Abstract] [Full Text] [Related]

  • 4. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C, Fountzilas G.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Warm M, Bauknecht T, Schröder W, Olbricht S, Nitz U, Jackisch C.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S, Ogasawara T, Ito K, Koyama M, Nagano T, Suzuki A, Yamada T, Nakata Y, Ozawa M.
    Oncol Rep; 2001 Oct; 8(2):285-8. PubMed ID: 11182041
    [Abstract] [Full Text] [Related]

  • 9. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC.
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract] [Full Text] [Related]

  • 10. [A case of ovarian cancer stage IV and advanced rectal cancer responding to paclitaxel/carboplatin].
    Kawaguchi R, Furukawa N, Morimoto Y, Ohi M, Osawa T, Koike H, Miyake T.
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):619-22. PubMed ID: 15114712
    [Abstract] [Full Text] [Related]

  • 11. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Apr; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 12. [Paclitaxel/carboplatin in first line treatment of advanced ovarian carcinoma].
    Meerpohl HG.
    Praxis (Bern 1994); 1999 Mar 18; 88(12):513-8. PubMed ID: 10235026
    [Abstract] [Full Text] [Related]

  • 13. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF.
    Semin Oncol; 2000 Jun 18; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [Abstract] [Full Text] [Related]

  • 14. Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer.
    Brown JV, Rettenmaier MA, Dillman RA, Birk CL, Culkin K, Micha JP.
    Gynecol Oncol; 1998 Feb 18; 68(2):166-8. PubMed ID: 9514805
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY, Barnes MN, Niwas S, Robertson MW, Alvarez R, Austin JM, Kilgore LC, Partridge EE.
    Gynecol Oncol; 1998 Feb 18; 68(2):178-82. PubMed ID: 9514799
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of recurrent ovarian cancer].
    Kudo R, Sagae S.
    Gan To Kagaku Ryoho; 1992 Oct 18; 19(12):1991-7. PubMed ID: 1358032
    [Abstract] [Full Text] [Related]

  • 18. Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer.
    Bolis G, Scarfone G, Villa A, Parazzini F.
    Gynecol Oncol; 2001 May 18; 81(2):331-3. PubMed ID: 11330974
    [No Abstract] [Full Text] [Related]

  • 19. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E, AGO-OVAR, GINECO.
    J Natl Cancer Inst; 2006 Aug 02; 98(15):1036-45. PubMed ID: 16882940
    [Abstract] [Full Text] [Related]

  • 20. Update on the management of ovarian cancer.
    Ozols RF.
    Cancer J; 2002 Aug 02; 8 Suppl 1():S22-30. PubMed ID: 12075699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.